Â鶹´«Ã½

Brief of the Â鶹´«Ã½ Trade Commission as Amicus Curiae before the United States District Court for the Eastern District of Pennsylvania, addressing whether a branded company's commitment not to launch an authorized generic in competition with a generic company can constitute a reverse payment under the Supreme Court’s ruling in FTC v. Actavis, 133 S. Ct. 2223 (2013), and describing the Commission’s review of pharmaceutical patent settlement agreements under the Medicare Modernization Act of 2003.